U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H22BrN3O2
Molecular Weight 344.247
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMOPRIDE

SMILES

CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC

InChI

InChIKey=GIYAQDDTCWHPPL-UHFFFAOYSA-N
InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)

HIDE SMILES / InChI

Description

Bromopride is a dopamine D2 receptor blocker. Bromopride exerts is a gastrointestinal prokinetic exploited clinically for the management of motor disorders of the upper gastrointestinal tract, including functional dyspepsia, gastric stasis of various origins and emesis.

CNS Activity

Originator

Soc. d'Etudes Sci. de l'Ile-de-France
2
Curator's Comment: reference retrieved from www.drugfuture.com/chemdata/bromopride.html

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Bromopan

Approved Use

Principais: distúrbios digestivos psicossomáticos ad senectude e da estafa mental. Discinesias gastroduodenais e biliares. Colopatias espasmódicas. Enxaquecas e mal-estar de origem celíaca. Náuseas. Vômitos. Anorexia. Particulares: exames radiológicos do tubo digestivo. Preparação de explorações endoscópicas. Vômitos anestésicos. Soluços. Meteorismo abdominal pós-operatório. Manifestações digestivas após a aplicação de radioterapia.
PubMed

PubMed

TitleDatePubMed
Mirtazapine (Remeron) as treatment for non-mechanical vomiting after gastric bypass.
2005 May
Validated method for determination of bromopride in human plasma by liquid chromatography--electrospray tandem mass spectrometry: application to the bioequivalence study.
2005 Sep
Case-crossover study of Burkholderia cepacia complex bloodstream infection associated with contaminated intravenous bromopride.
2010 May
Patents

Patents

US3177252
2

Sample Use Guides

In Vivo Use Guide
Capsules: 40-60 mg/day Oral solution: 40-60 mg/day (adults), 0.5-1 mg/kg (children)
Route of Administration: Oral
In Vitro Use Guide
Bromopride effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM. Bromopride can inhibit cholinesterase activity in all tissues studied,
Name Type Language
BROMOPRIDE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
BROMOPRIDE [MI]
Common Name English
bromopride [INN]
Common Name English
NSC-758391
Code English
MOVIPRIDE
Brand Name English
BROMOPRIDE [MART.]
Common Name English
4-AMINO-5-BROMO-N-(2-(DIETHYLAMINO)ETHYL)-O-ANISAMIDE
Common Name English
Bromopride [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC A03FA04
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
NCI_THESAURUS C66883
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
NCI_THESAURUS C267
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
WHO-VATC QA03FA04
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
Code System Code Type Description
PUBCHEM
2446
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
INN
3142
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
FDA UNII
75473V2YZK
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
SMS_ID
100000088697
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
RXCUI
19768
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY RxNorm
MESH
C013855
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
WIKIPEDIA
BROMOPRIDE
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
DRUG CENTRAL
406
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
DRUG BANK
DB09018
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
CAS
4093-35-0
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
NCI_THESAURUS
C73035
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
EPA CompTox
DTXSID0045383
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
ChEMBL
CHEMBL399510
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
ECHA (EC/EINECS)
223-842-2
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
MERCK INDEX
m2713
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY Merck Index
NSC
758391
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
EVMPD
SUB05921MIG
Created by admin on Fri Dec 15 16:02:29 UTC 2023 , Edited by admin on Fri Dec 15 16:02:29 UTC 2023
PRIMARY
ACTIVE MOIETY
Structure of BROMOPRIDE
SALT/SOLVATE (PARENT)
Structure of BROMOPRIDE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966